Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis.

Edgar Gerardo Dorsey-TreviñoJ G González-GonzálezN Alvarez-VillalobosV González-NavaB M Contreras-GarzaA Díaz González-ColmeneroG Rodríguez-TamezF J Barrera-FloresA M FarrellV M MontoriR Rodriguez-Gutierrez

Published in: Journal of endocrinological investigation (2019)

SGLT-2 inhibitors may reduce the risk of renal patient-important outcomes but fail to improve surrogate outcomes. Apparently, no increased risk of amputations was observed with these medications. No data were available regarding other microvascular complications.

Keyphrases

case report
risk factors
type diabetes
electronic health record
metabolic syndrome
adipose tissue
skeletal muscle
insulin resistance